Balixafortide (POL6326) is an orally bioavailable peptidic CXC chemokine receptor 4 (CXCR4) antagonist.
POL6326 enhances systolic function in a porcine closed-chest model of reperfused acute MI. POL6326 mobilizes Treg cells, enhances Treg cell recruitment to the infarct, attenuates tumor necrosis factor expression in monocytes and macrophages in the infarcted region, enhances infarct border-zone capillarization, reduces infarct scar size, and attenuates LV remodeling and systolic dysfunction in mice.[2]
[1] Darja Karpova, et al. J Transl Med. 2017 Jan 3;15(1):2. [2] Yong Wang, et al. Circulation. 2019 Apr 9;139(15):1798-1812.